Neurocan-M
A fragment of neurocan cleaved by matrix metalloproteinase-2, enabling non-invasive monitoring of extracellular matrix remodeling and blood-brain barrier integrity in neurodegenerative conditions.
Key features and values
- Quantifies neurocan fragments indicative of extracellular matrix remodeling.
- Reflects alterations in blood-brain barrier integrity associated with neurodegenerative conditions.
- Provides a non-invasive measure of central nervous system extracellular matrix dynamics.
- Supports monitoring of disease progression and response to therapies targeting neurodegeneration.
- Applicable in research on diseases characterized by aberrant extracellular matrix turnover in the central nervous system.
- Facilitates evaluation of interventions aimed at modulating extracellular matrix degradation in neurological disorders.
- Complements other biomarkers for a comprehensive assessment of neurodegenerative disease mechanisms.
Description
The Neurocan-M biomarker assay measures specific fragments of neurocan resulting from matrix metalloproteinase-2-mediated cleavage, serving as an indicator of extracellular matrix remodeling and blood-brain barrier integrity in neurodegenerative conditions. This non-invasive assay provides insights into central nervous system extracellular matrix dynamics associated with neurological disorders. By quantifying neurocan degradation products, the Neurocan-M assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of neurodegeneration and blood-brain barrier disruption. It serves as a valuable tool in research settings for assessing the dynamics of extracellular matrix turnover in the central nervous system.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
